The global cell line development market grows steadily with a predicted revenue of $7.5bn by 2024, each component of the market to see CAGR between 10-15%.
Agilent Technologies says it is benefitting from increased antibody and biosimilar R&D and manufacturing, reporting a double-digit growth for its third quarter.
Samsung Biologics wants Big Pharma to up biomanufacturing outsourcing and says lessons learned from the semiconductor industry will give it the advantage in the CMO space.
Biologics contracting drove growth in fiscal Q3 according to Catalent, which predicted the proportion of revenue it generates from large molecule work will continue to increase.
Avid Bioservices will add multiple MilliporeSigma 2,000L bioreactors at its Californian single-use production plant in an effort to its increase annual revenue to over $100m.
Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.
Thermo Fisher Scientific, Inc. saw revenue grow 8% in 2016, mostly due to acquisitions of new Chromotography and mass spectrometry tech and expanding its Bioproduction.
Avid Bioservices has reported strong contract manufacturing revenues for its Q2 and is confident a planned third facility will not leave the firm with too much capacity.
Catalent has more than doubled its biologics business since it went public in 2014, but the sector still represents less than 5% of the CDMO’s revenues.
Charles River says it is capitalising on the growing number of biologics in development, with its manufacturing business seeing double-digit growth led by demand for biosafety and cell banking services.
A new single-use bioproduction plant will bring in annual revenues of $40m, says Avid Bioservices which is already eyeing up additional capacity to cope with contract manufacturing demand.
Sartorius finished the first half of 2015 with increased sales, higher operating profits and a surge in orders that prompted it to raise its full year forecast.
Amgen has benefited from enhanced regulatory discussions surrounding biosimilars, the firm says, as it develops a pipeline of nine products alongside its own biologics.
WuXi PharmaTech has reported a 23% growth in manufacturing services and is planning to build a commercial biomanufacturing facility to meet the strong demand for biologics.
Repligen has invested $4m (€3.2m) in its Massachusetts manufacturing facility in order to support the fermentation cell retention technology acquired from Refine.
Extra filling capacity is to be made available in preparation for West’s Crystal Zenith (CZ) system, though approval and increased sales are still at least 18 months away.
High tech packaging sales and revenue from acquired delivery businesses drive West Pharmaceutical Services growth in second quarter, but US firm cuts guidance.
Charles River Laboratories (CRL) is to acquire WuXi PharmaTech for $1.6bn (€1.2bn), creating a global CRO capable of offering fully integrated services from molecule creation to first-in-human testing.
Faced with a tougher operating environment, Irish drugmaker Elan has decided to slash staff numbers by 230 – or around 14 per cent of its total workforce – shelve the construction of a new biologics manufacturing facility and shutter fill-and-finish capacity...
Drug packaging maker West Pharmaceutical Services release its 3Q
results, which indicate a rise in profits but fell short of analyst
estimates, due to slow sales in some segments and high raw material
and energy costs.
